Prism Capital Partners has completed the first phase of major infrastructure improvements at its ON3 campus in Nutley and Clifton, as it continues to ready the site for new tenants and additional construction.
Prism Capital Partners is poised to move forward with its redevelopment of five acres in downtown Woodbridge, where it’s planning a mixed-use project with more than 230 apartments.
Prism Capital Partners has launched nearly $10 million in roadway and utility upgrades at the former Hoffmann-LaRoche campus in Nutley and Clifton, as it prepares to welcome new tenants to the 116-acre redevelopment site.
I am convinced more than ever that forward-thinking New Jersey suburbs are poised for a comeback. Many city residents, especially those in their 20s and 60s will seek alternate residences. Towns that have invested in their infrastructure and assets for the long term and are ready to accommodate this exodus of consumers and their preferences will be able to compete for this wealth of talent and the resources they bring to the community.
A team of Monmouth University students earned top honors recently at NAIOP New Jersey’s annual Intercollegiate Case Study Competition, offering a vision for redeveloping the former Hoffmann-LaRoche campus in Nutley and Clifton.
Less than a month after hosting a forum for local residents and other stakeholders, the former Hoffmann-LaRoche campus will welcome aspiring commercial real estate professionals.
For all the time we’ve spent highlighting New Jersey’s glut of sprawling, vacant corporate campuses, it’s easy to lose sight of just how many of them have been rescued in recent years by some of the state’s boldest and most inventive developers. Those success stories are worth telling, which is why we often do at Real Estate NJ. But there are underlying trends or nuances in some of those projects that don’t get as much attention on a day-to-day basis. Like how a crop of innovative, lesser-known biotech and pharmaceutical firms are backfilling space at the former research campuses of Sanofi and Hoffmann-LaRoche, helping to stabilize those sites as their new owners pursue larger redevelopment plans.